Department of Obstetrics and Gynecology, The First Affiliated Hospital of USTC, Division of Life, Sciences and Medicine, University of Science and Technology of China, Hefei 230031, China.
Department of Obstetrics and Gynecology, The First Affiliated Hospital of USTC, Division of Life, Sciences and Medicine, University of Science and Technology of China, Hefei 230031, China.
Biomed Pharmacother. 2022 Feb;146:112504. doi: 10.1016/j.biopha.2021.112504. Epub 2021 Dec 15.
CEMIP was initially identified as an inner-ear specific protein in which three-point mutations cause folding changes in protein structure associated with non-syndromic hearing loss. CEMIP was also involved in other cellular activities, such as hyaluronan depolymerization independent of CD44 and other hyaluronidases. Growing evidence has demonstrated that CEMIP is involved in the progression of various tumors. However, whether the oncogenic effects of CEMIP relies on its enzymatic activity remain elusive. CEMIP is significantly related to metastasis and poor prognosis in patients with various tumors, suggesting that CEMIP is a potential, highly specific diagnostic tumor marker. Most preclinical experiments have shown that the overexpression of CEMIP in tumors mainly affects the adhesion, metastasis, and invasion of tumor cells and EMT. Other studies have also demonstrated that CEMIP can promote a variety of tumor processes by affecting tumor proliferation, dedifferentiation, and the tumor microenvironment. In terms of molecular mechanisms, existing research has shown that CEMIP mainly affects the WNT and EGFR signaling pathways. In addition, a variety of miRNAs have been shown to inhibit CEMIP in tumors. This paper elaborates on the clinical characteristics and regulatory dysfunction of CEMIP in different cancers. CEMIP provides a new potential target for therapy of multiple tumors, which is worthy of further study.
CEMIP 最初被鉴定为内耳特异性蛋白，其中三个点突变导致与非综合征性听力损失相关的蛋白质结构折叠变化。CEMIP 还参与其他细胞活动，如透明质酸解聚不依赖于 CD44 和其他透明质酸酶。越来越多的证据表明，CEMIP 参与了各种肿瘤的进展。然而，CEMIP 的致癌作用是否依赖于其酶活性仍不清楚。CEMIP 与多种肿瘤患者的转移和预后不良显著相关，提示 CEMIP 是一种潜在的、高度特异性的诊断肿瘤标志物。大多数临床前实验表明，CEMIP 在肿瘤中的过表达主要影响肿瘤细胞的黏附、转移和侵袭以及 EMT。其他研究还表明，CEMIP 可以通过影响肿瘤增殖、去分化和肿瘤微环境来促进多种肿瘤过程。就分子机制而言，现有研究表明，CEMIP 主要影响 WNT 和 EGFR 信号通路。此外，多种 miRNA 已被证明可在肿瘤中抑制 CEMIP。本文详细阐述了 CEMIP 在不同癌症中的临床特征和调控功能障碍。CEMIP 为多种肿瘤的治疗提供了一个新的潜在靶点，值得进一步研究。
